RESULTS:
The 117 essential medicines on the model list accounted for 44% of all prescriptions and 30% of total prescription drug expenditures in 2015. Average prices of generic essential medicines were 47% lower in the US, 60% lower in Sweden and 84% lower in New Zealand; brandname drugs were priced 43% lower in the US. Esti mated savings from universal public coverage of these essential medicines was $4.27 billion per year (range $2.72 billion to $5.83 billion; 28% reduction) for patients and private drug plan sponsors, at an incremental government cost of $1.23 billion per year (range $373 million to $1.98 bil lion; 11% reduction).
INTERPRETATION:
Our analysis showed that adding universal public coverage of essential medicines to the existing pub lic drug plans in Canada could address most of Canadians' pharmaceutical needs and save billions of dollars annu ally. Doing so may be a pragmatic step forward while more comprehensive pharmacare reforms are planned. Cana da's purchasing power in the global pharmaceutical mar ket. 10 As a result, pharmaceutical prices and total per capita ex penditures on pharmaceuticals are higher in Canada than in de veloped countries with comparable health care systems. [10] [11] [12] [13] Universal public coverage of prescription drugs was recom mended by the 1964 Royal Commission on Health Services (Hall Commission), the 1997 National Forum on Health and the 2002 Royal Commission on the Future of Health Care in Canada (Romanow Commission) . 14 These commissions, and more recent bodies of evi dence, suggest that implementing universal public drug coverage that is both comprehensive and evidence based would be the best way to ensure the accessibility, affordability and appropriateness of medicine use in Canada. 15 But a variety of factors have stalled prog ress toward such universal pharmacare. 16 Practical considerations are among obstacles to reform. Imple menting a comprehensive pharmacare program involves a number of logistical challenges: a national, evidencebased formulary needs to be delineated; prices and supply contracts need to be negotiated; and a greater share of total pharmaceutical expenditure needs to flow through the public program. Although these challenges are not insurmountable, it may be prudent to "start small" by adding uni versal public coverage of a carefully selected list of essential medica tions to the existing complement of public drug plans in Canada. A similar step toward comprehensive drug coverage for all Canadians was recommended by the 2002 Romanow Commission and the 2016 Citizens' Reference Panel on Pharmacare in Canada. 17, 18 The World Health Organization (WHO) maintains a model list of essential medicines that is meant to be adapted by countries to meet the medicine needs of their populations. 19, 20 Medicines on resulting national lists are ones governments commit to mak ing accessible because of their importance to patient and public health. 21, 22 International evidence suggests that encouraging access to drugs on essential medicine lists can improve patient outcomes and lower costs. [22] [23] [24] [25] [26] [27] [28] We sought to estimate the 2015 volume and cost of prescrip tions filled in Canada for medicines on, or similar to medicines on, a Canadian adaptation of the World Health Organization's model list of essential medicines. We also sought to compare the prices of these essential medicines in Canada with their prices within singlepayer systems for pharmaceutical coverage that publish data on drug pricing: the US Department of Veterans Affairs, and the national drug coverage systems of Sweden and New Zealand. Finally, we sought to estimate the financial impli cations of adding universal public drug coverage of the essential medicines on the model list to the existing complement of public drug plans in Canada.
Methods
This is a secondary analysis of administrative and market research databases pertaining to the volume and costs of pre scriptions for the calendar year 2015.
Selection and classification of medicines
The essential medicines list used in our study is the CLEAN Meds list, an adaptation of the WHO model list of essential medicines for primary health care in Canada. 29 Our analysis focused on 117 of the CLEAN Meds drugs (hereafter "the essential medicines") that are available and sold as prescriptiononly medicines in Canada (Appendix 1, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.161082//DC1). Although predominantly target ing primary health care needs, some medicines on the list are often prescribed by specialists (e.g., treatments for hepatitis and HIV infection, and a biologic drug for inflammatory conditions).
We used WHO's Anatomic Therapeutic Chemical (ATC) Classifi cation System to assign medicines to mutually exclusive groups. 30 This allowed us to identify other drugs for which the essential medi cines may be suitable substitutes for some patients. We used the chemical subgroups of the ATC system to define relatively close substitutes (e.g., A02BC = "proton pump inhibitors") and the phar macologic/therapeutic subclasses of the ATC system to define broader ranges of substitutes (e.g., A02B = "drugs for peptic ulcer and gastrooesophageal reflux disease"). We further grouped medi cines into 47 broad therapeutic categories for reporting purposes.
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Data sources
We used data from multiple sources, each described in greater detail in Appendix 2 (available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.161082//DC1). From IMS Health, we obtained productlevel data describing the number of and total expendi ture on all prescriptions dispensed at retail pharmacies in each province during 2015. From the National Prescription Drug Utili zation Information System database of the Canadian Institute for Health Information (CIHI), we obtained 2015 data on the number of and total expenditure on prescriptions that were paid, in whole or in part, by public drug plans in all provinces except Quebec. Because the IMS Health data included Quebec but the CIHI data did not, we estimated the public shares of prescription costs for Quebec based on average public shares for the same drug types in all other provinces combined. This may overstate the public proportion of expenditures in Quebec by 7% (Appendix 2).
Using methods described in Appendix 2, we obtained prices for the most common dosage forms of each generic drug on the essential medicines list from public formularies in Canada, the United States (US Department of Veterans Affairs), Sweden and New Zealand. Because prices of brandname drugs listed on national formularies do not include confidential manufacturers' rebates, we obtained from the US Department of Veterans Affairs a weighted average of net prices of essential medicines available only from brandname manufacturers in Canada. We converted foreign prices for generic and brandname drugs to Canadian dollars using 2 methods: exchange rates and gross domestic product (GDP) purchasing power parities.
Statistical analysis
To measure the baseline volume of prescriptions used, we com puted the total number and cost of prescriptions for the essential medicines and all other medicines in 2015. To gauge the poten tial scope of clinical needs that the essential medicines may be suitable for, we calculated the number and cost of prescriptions in the same ATC chemical subgroups and the same ATC pharma cologic subclasses as 1 or more of the essential medicines.
We used economic modelling to estimate the total cost of prescriptions (stratified by province, therapeutic category and source of financing) under a scenario wherein universal public coverage of the essential medicines is added to the existing com plement of public drug plans in Canada. The models were based on economic frameworks developed for analyses of the determi nants of prescription drug expenditure as a function of the vol ume of purchases made, products selected and prices paid for selected products. 32, 33 The economic models involved a number of pricing and utili zation parameters that we chose on the basis of Canadian and international evidence, as described in Appendix 2 and summa rized in Table 1 . We report results for scenarios with all model parameters set to basecase scenario values, all parameters set 
Results
Baseline volume and cost of prescriptions
In 2015, Canadians filled an estimated 568.4 million prescriptions at retail pharmacies, at a total cost of $26.2 billion (Table 2) . A to tal of 377.5 million of the prescriptions were publicly paid, at a total cost of $10.8 billion. The essential medicines accounted for 44% of all prescriptions and 30% of the total cost. They ac counted for a slightly higher share (50%) of publicly paid pre scriptions and an approximately equal share (31%) of the total expenditure on publicly paid prescriptions. The essential medicines accounted for 50% or more of pre scriptions from 15 broad therapeutic categories, including highprescriptionvolume drug classes (e.g., drugs for chronic obstructive pulmonary disease and asthma, drugs for ulcers and gastroesophageal reflux disease, noninsulin diabetes medi cations and antibiotics). (Results by drug category are available in Appendix 1.) There were no essential medicines listed for 7 treatment categories: hepatitis C, bladder control, infertility, macular degeneration and receptorpositive cancers (endo crine therapies).
Greater shares of prescription volumes and expenditures were accounted for by the essential medicines combined with drugs that were either chemically or pharmacologically similar to them. Medicines from ATC chemical subclasses that had 1 or more of the essential medicines within them accounted for 77% of total pre scriptions filled and 63% of total prescription expenditures. Medi cines from ATC pharmacologic subclasses with 1 or more of the essential medicines within them accounted for 90% of total pre scriptions filled and 83% of total prescription expenditures. Table 3 summarizes our comparison of the relative price of generic versions of the essential medicines in Canada and in comparable countries. We were able to find comparator generic 
Foreign prices of essential medicines
Cost of universal coverage of the essential medicines
For Canada and each province separately, Table 4 lists the esti mated change in total (private and public) expenditure on all prescriptions filled in retail pharmacies under our scenarios for adding universal public coverage of the essential medicines to the existing complement of public drug plans in Canada.
We estimated that the total expenditure on prescription drugs in Canada would fall by $3.04 billion (range $743 million to $5.46 billion; 12% reduction) under such an expansion of public Expenditureweighted average relative price of generic versions of essential medicines, comparator country relative to Canada, % Using 5year average exchange rates to convert currencies 53 40 16 Using GDP purchasing power parities to convert currencies 47 44 16
Note: GDP = gross domestic product. coverage. The percentage reduction in total expenditure was about equal across the provinces: ranging in the base scenario from a 9% reduction in Alberta to a 13% reduction in Ontario and New Brunswick. All economic scenarios included a total of more than $6 billion in pharmacy dispensing fees, equivalent to more than $210 000 per pharmacist practising in the community set ting in Canada. 42 For Canada as a whole, Table 5 summarizes our estimates of the change in public and private expenditures on all prescrip tions filled in retail pharmacies under our scenarios with the addition of universal public coverage of the essential medicines. We estimated that the incremental government cost of adding universal public coverage of the essential medicines would be $1.23 billion per year (range $373 million to $1.98 billion; 11% reduction). The incremental private sector savings from such coverage was estimated at $4.27 billion per year (range $2.72 bil lion to $5.83 billion; 28% reduction). Total public expenditure on the essential medicines was estimated at $6.14 billion (range $5.6 billion to $6.6 billion); total public expenditure on medicines not on the essential medicines list, yet currently covered under existing public drug plans, was estimated at $5.85 billion (range $5.53 billion to $6.13 billion).
Almost half of the estimated total national savings from add ing universal public coverage of the essential medicines ($1.50 billion) came from 7 therapeutic categories of medicine commonly prescribed in primary care: acidreducing drugs, cholesterol medicines, antihypertensives, antipsychotics, anti biotics, antidepressants, and gabapentin and related drugs (Appendix 1). In contrast, about half ($628 million) of the incre mental cost to government of covering the essential medicines stemmed from increased public expenditure on just 1 drug: adalimumab (Humira).
Interpretation
We found that nearly half (44%) of all prescriptions filled at re tail pharmacies in Canada in 2015 were for 117 drugs on a model essential medicines list for Canada (the CLEAN Meds list 29 ). An additional 33% of prescriptions filled were for drugs from the same chemical subclasses as 1 or more medicine from the essential medicines list. We estimated that adding universal public coverage of the essential medicines to the ex isting complement of public drug plans in Canada would save patients and private drug plan sponsors $4.27 billion per year (range $2.72 to $5.83 billion; 28% reduction). The incremental government cost of adding such coverage was estimated at $1.23 billion per year (range $373 million to $1.98 billion; 11% reduction). These estimates do not include indirect govern ment savings from reduced cost of private drug coverage for public sector employees, patient savings from shopping at pharmacies with low dispensing fees, or reduced demands on the health system stemming from increased adherence to essential therapies.
Our modelling produced financial results similar to those found in the actual implementation of a limited formulary in Sweden. Adherence to the Swedish "Wise List" in Stockholm pri mary care sites saved 28% annually (€10 million or Can$14.5 mil lion). 43 If our economic models were set up to exclude the cost impact of increases in utilization resulting from insuring previ ously under and uninsured people (which was not a factor under Sweden's universal system of drug coverage), they would pro duce estimated net savings of 23% ($3.7 billion) within the drug classes directly affected by the essential medicines list modelled for Canada.
Our findings are also consistent with a previous study that estimated a comprehensive public drug plan could reduce total annual pharmaceutical expenditure in Canada by $7.3 billion using data from the 2012/13 fiscal year. 41 If our results were scaled to include savings for drugs not on the essential medi cines list, the basecase scenario estimates of total annual sav ings would be between $6.9 billion and $10.1 billion using data for the calendar year 2015.
Reflecting the incremental approach to policy development modelled here, our present estimates of the public cost of adding universal public coverage of essential medicines to the existing complement of public drug plans in Canada are lower than the previous estimates of the public cost of a universal, comprehen sive public drug plan. The estimated gross cost to governments (excluding indirect savings on public sector employee benefits) is $1.2 billion for coverage of essential medicines in 2015, as com pared with the estimated $3.4 billion for comprehensive public drug coverage in 2012/13.
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Limitations
As a simulation study, our analysis is necessarily based on assumptions concerning changes in drug utilization, product substitutions and prices. We have based our assumptions on available evidence and direct price comparisons described in the Appendix 2. To account for the range of possible outcomes, we present results with all parameters set to bestcase scenario values and all parameters set to worstcase scenario values. We were unable to compare netofrebate prices in Canada with those in each of the comparator countries in this study. However, from the US Department of Veterans Affairs, we obtained an estimate of the weightedaverage netofrebate prices for essential medicines available only from brandname manufacturers in Canada. Those prices were 43% lower than Canadian list prices, which suggests that our assumptions about possible changes in net brandname prices for the essential med icines are conservative (Appendix 2).
Finally, we modelled the implications of just one example of an essential medicines list that could be used as a first stage of pharmacare reform for Canada. Changes in the number and type of drugs included on the list will affect financial impacts of expanding drug coverage in this way. Provided that the list in cludes 1 or more generic drugs from the highvolume chemical subclasses of medicines that account for most medication use in Canada today (as the CLEAN Meds list does), the financial im pacts of coverage of such treatment types will be similar to those modelled here. Expanding coverage to include additional therapeutic categories will broaden the extent of needs met and savings potential from the universal public system, but it will also increase the incremental costs to government of such a program, which would bring this incremental approach to phar macare development closer to the comprehensive approach modelled previously.
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Conclusion
Commissions on the Canadian health care system have repeat edly concluded that universal, comprehensive public pharma care is the most equitable and efficient means of achieving access to appropriate and affordable care for all Canadians. Our study showed that adding universal public coverage of a model list of essential medicines to the existing complement of public drug plans in Canada could address most of Canadians' pharma ceutical needs and save billions of dollars annually. Doing so may be a pragmatic step forward while more comprehensive pharma care reforms are planned.
